1. Home
  2. SYRE

SYRE

Spyre Therapeutics Inc.

Logo Spyre Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.

Founded: 2013 Country:
United States
United States
Employees: N/A City: WALTHAM
Market Cap: 1.4B IPO Year: 2016
Target Price: $38.00 AVG Volume (30 days): 497.4K
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -49.12 EPS Growth: N/A
52 Week Low/High: $2.65 - $47.97 Next Earning Date: 05-09-2024
Revenue: $886,000 Revenue Growth: -61.96%
Revenue Growth (this year): 1051.24% Revenue Growth (next year): -25.00%

Share on Social Networks: